Articles

SLAS 2020 Show Preview: SLAS in the sun

The Society for Laboratory Automation and Screening heads to San Diego for SLAS 2020
Written byMel J. Yeates
| 14 min read

Society for Laboratory Automation and Screening (SLAS)

SLAS 2020 International Conference & Exhibition

San Diego Convention Center

San Diego, California

January 25-29, 2020

SLAS in the sun

The Society for Laboratory Automation and Screening heads to San Diego for SLAS 2020

By Mel J. Yeates

SAN DIEGO—Data will be one of the key focuses of the SLAS 2020 International Conference and Exhibition, as the Society for Laboratory Automation and Screening (SLAS) comes to sunny San Diego for some warm(er) weather in January.

DDNews spoke with both Melanie Leveridge, the director of Screening, Profiling & Mechanistic Biology at GlaxoSmithKline (GSK) and conference chair for SLAS 2020, and Mike Tarselli, SLAS’s scientific director, to gain insight about the upcoming meeting.

“With 10 conference tracks in the scientific program alongside an array of short courses, vendor tutorials and special interest groups, there is educational scientific content for everyone, whether you are a student researcher or experienced academic or drug discovery scientist. The vendor exhibition is packed full of cutting-edge technologies and is a great place to catch up with old colleagues and make many new connections,” says Leveridge. “Just take some comfy shoes, as you will cover a lot of ground.”

“We’re welcoming four new courses this year with topics ranging from Python and Data Analysis to pharmacological target engagement, which seeks to unravel why up to 50 percent of new drugs candidates wash out due to low efficacy against their targets,” adds Tarselli. “We’re also proud to offer selected talks, panels and podcasts on our (still new) online learning system, APPLIED.”

Leveridge points out, “For 2020, we have an overarching data theme, and in particular how artificial intelligence (AI) and access to ‘Big Data’ is changing the way we conduct drug discovery.”

“Other themes you’ll see throughout our conference will focus on functional genomics, which studies how biological gene networks contribute to a specific disease phenotype, and protein homeostasis, which advances pragmatic ideas about how regulation of protein concentrations through stabilization or degradation can ameliorate specific conditions,” Tarselli mentions.

“In addition to the Data Analysis and Informatics track, which has grown in attendance exponentially over the last couple of years, we also have two great keynote speakers who represent this field: Jackie Hunter from Benevolent AI and Leroy Cronin from the University of Glasgow, who will talk about AI-augmented drug discovery and the concept of ‘chemputing,’ respectively,” Leveridge states.

Hunter, who will be delivering the opening keynote speech, has more than 30 years of experience in the bioscience research sector across academia and industry, including leading neurology and gastrointestinal drug discovery and early clinical development for GSK. She now leads BenevolentAI, which uses AI to augment the research capability of drug scientists—from target identification and validation through medicinal chemistry and lead optimization, to clinical proof of concept.

Cronin’s group at the University of Glasgow has one of the largest multidisciplinary chemistry-based research teams in the world. The team is developing the concept of “chemputing,” which enables the universal digitization of chemistry in order to create artificial life forms, find alien life, further explore the digitization of chemistry, understand how information can be encoded into chemicals and construct chemical computers. Cronin will deliver the closing keynote for SLAS 2020.

SLAS has highlighted a few sessions and tracks of particular interest to DDNews’ readers.

“This year, for the first time, we have a track dedicated to precision medicine. This track will explore capabilities such as single-cell technologies and patient-derived cell systems, which enable high-throughput and high-resolution approaches to study disease in a more patient- and cell subtype-specific context,” Leveridge explains. “Ultimately these approaches should enable us to build assays and cell models that more readily translate into the clinic, which is really exciting.”

Leveridge tells DDNews that there have been some changes in this year’s programming, stating that “In putting together the scientific program for 2020, we wanted to offer much more than a collection of individual presentations. We have therefore identified opportunities for attendees to explore and critically evaluate themes that span several areas of technical focus and promise to raise drug discovery and biomedical research to the next level. Examples of such themes, which traverse multiple tracks, are the use of AI and machine learning (ML) as decision-making tools, strategies to confirm target engagement in vitro and in vivo, and approaches for targeting protein homeostasis.”

“The SLAS Ignite initiative is definitely worth highlighting,” she continues. “The aim of Ignite is to facilitate connections that result in pioneering new research, new products, innovative breakthroughs and commercialization opportunities. For 2020, we have two Ignite panel discussions where leaders in the field will discuss ‘Success stories in launching commercial products from initial ideas’ and ‘How diversity drives entrepreneurial success.’ There is also an Ignite short course in ‘How to articulate value propositions in scientific innovation.’”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A researcher wearing a white lab coat and blue nitrile glove holds a tiny brown glass sample vial with a blue cap in front of an autosampler carousel on a HPLC laboratory analyzer.
Hear an expert perspective on the hidden variables affecting chromatographic methods and how to build more robust, reliable workflows.
Researcher using a laptop with a digital DNA helix and molecular biology graphics overlaid, illustrating connected workflows for sequence design, data management, and therapeutic research.
To keep pace with modern drug discovery, researchers need molecular biology approaches that can support complexity without slowing down the science.
Shaping Science graphic featuring the question “How can labs become truly sustainable?” and a photo of James Connelly, Chief Executive Officer of My Green Lab.
Creating more sustainable laboratories depends on practical changes that strengthen scientific performance while reducing environmental impact.